- Home
- STRO vs MDXG Comparison
STRO vs MDXG Comparison
Compare STRO & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | MDXG |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | 133 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.8M | 530.2M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | STRO | MDXG |
|---|---|---|
| Price | $26.85 | $3.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $31.33 | $9.00 |
| AVG Volume (30 Days) | 303.0K | ★ 1.2M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $0.67 | $3.03 |
| 52 Week High | $43.85 | $7.99 |
Technical Indicators
Market Signals| Indicator | STRO | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 51.25 |
| Support Level | $23.53 | $3.47 |
| Resistance Level | $27.96 | $3.80 |
| Average True Range (ATR) | 2.87 | 0.12 |
| MACD | -0.33 | 0.01 |
| Stochastic Oscillator | 40.44 | 50.00 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.